|
UBE3A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.17189591364308E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.18939996424695E-09 |
| Normal-vs-Stage2 |
5.22110000011899E-07 |
| Normal-vs-Stage3 |
3.68299835074026E-11 |
| Normal-vs-Stage4 |
1.41749945115066E-11 |
| Stage1-vs-Stage2 |
5.571200E-01 |
| Stage1-vs-Stage3 |
4.338100E-02 |
| Stage1-vs-Stage4 |
2.776100E-03 |
| Stage2-vs-Stage3 |
3.837600E-01 |
| Stage2-vs-Stage4 |
1.012840E-01 |
| Stage3-vs-Stage4 |
3.426400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93199900522245E-11 |
| Normal-vs-AfricanAmerican |
1.163500E-02 |
| Normal-vs-Asian |
1.13579999849733E-08 |
| Caucasian-vs-AfricanAmerican |
1.056360E-01 |
| Caucasian-vs-Asian |
5.340400E-01 |
| AfricanAmerican-vs-Asian |
1.180620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.43419761914288E-11 |
| Normal-vs-Female |
1.88750015617245E-10 |
| Male-vs-Female |
6.183200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.35439999718423E-08 |
| Normal-vs-Age(41-60Yrs) |
1.74469994007609E-10 |
| Normal-vs-Age(61-80Yrs) |
1.0688999685371E-09 |
| Normal-vs-Age(81-100Yrs) |
3.997600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.461630E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.483640E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.055600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.439200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.679400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.734800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.736000E-03 |
| Classical-VS-Follicular |
4.010800E-01 |
| Classical-VS-Other |
4.460200E-01 |
| Classical-VS-Normal |
1.9914999649373E-09 |
| Tall-VS-Follicular |
5.474500E-02 |
| Tall-VS-Other |
5.902600E-01 |
| Tall-VS-Normal |
3.85670051450404E-10 |
| Follicular-VS-Other |
6.798000E-01 |
| Follicular-VS-Normal |
2.30629999986576E-07 |
| Other-VS-Normal |
4.899300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.46919953769986E-10 |
| Normal-vs-N1 |
1.05400022043511E-10 |
| N0-vs-N1 |
1.335960E-01 |
|
|
